{
    "nctId": "NCT00258375",
    "briefTitle": "OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Objective response measured by RECIST criteria after accrual of 14 evaluable patients",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Metastatic or locally advanced disease\n  * Not curable with standard therapy\n* Measurable disease, defined as \u2265 1 unidimensionally measurable lesion \u2265 20 mm by conventional techniques OR \u2265 10 mm by spiral CT scan\n\n  * Lesion must be outside of the previously irradiated field\n\n    * If the sole site of disease is in a previously irradiated field, there must be evidence of disease progression or new lesions in the irradiated field\n* No known CNS metastases\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 12 weeks\n\nHematopoietic\n\n* Platelet count \u2265 100,000/mm\\^3\n* Absolute granulocyte count \u2265 1,500/mm\\^3\n* PTT, PT, and INR normal\n* No known bleeding disorder\n\nHepatic\n\n* Bilirubin normal\n* AST and ALT \u2264 1.5 times upper limit of normal (ULN)\n\nRenal\n\n* Creatinine \u2264 1.5 times ULN\n\nCardiovascular\n\n* No significant cardiac dysfunction\n\nImmunologic\n\n* No active uncontrolled infection\n* No history of serious allergic reaction to taxanes, including paclitaxel or docetaxel\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No preexisting neuropathy \u2265 grade 2\n* No other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix\n* No other serious medical condition or illness that would preclude study participation\n* No significant neurological disorder that would preclude giving informed consent\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Prior trastuzumab (Herceptin\\^\u00ae) allowed\n\nChemotherapy\n\n* Recovered from prior chemotherapy\n* At least 6 months since prior adjuvant chemotherapy (taxanes allowed)\n* At least 4 weeks since prior chemotherapy for advanced disease\n\n  * No prior taxanes for advanced disease\n* No more than 1 prior chemotherapy regimen for advanced disease\n* No other concurrent chemotherapy\n\nEndocrine therapy\n\n* At least 1 week since prior hormonal therapy\n\nRadiotherapy\n\n* See Disease Characteristics\n* At least 4 weeks since prior radiotherapy\n\n  * Low-dose, nonmyelosuppressive radiotherapy allowed within 4 weeks before study entry at the discretion of the investigator\n* No prior radiotherapy \u2265 30% of functioning bone marrow\n* No concurrent radiotherapy\n\nSurgery\n\n* At least 3 weeks since prior major surgery and recovered (wound healing must have occurred)\n\nOther\n\n* More than 4 weeks since prior investigational agents or new anticancer therapy\n* No concurrent therapeutic anticoagulation therapy except low-dose oral anticoagulant therapy (i.e., 1 mg of oral warfarin once a day) or low molecular weight heparin\n* No other concurrent investigational therapy\n* No other concurrent cytotoxic therapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}